BioLineRx (BLRX) Competitors $4.24 +0.59 (+16.16%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.24 (-5.66%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. ADVM, INKT, QNTM, MNOV, COEP, IMMX, SLGL, ALXO, ANL, and KPTIShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Quantum Biopharma (QNTM), MediciNova (MNOV), Coeptis Therapeutics (COEP), Immix Biopharma (IMMX), Sol-Gel Technologies (SLGL), ALX Oncology (ALXO), Adlai Nortye (ANL), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Adverum Biotechnologies MiNK Therapeutics Quantum Biopharma MediciNova Coeptis Therapeutics Immix Biopharma Sol-Gel Technologies ALX Oncology Adlai Nortye Karyopharm Therapeutics BioLineRx (NASDAQ:BLRX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Do institutionals & insiders believe in BLRX or ADVM? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is BLRX or ADVM more profitable? Adverum Biotechnologies has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. BioLineRx's return on equity of -49.74% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-45.34% -49.74% -17.54% Adverum Biotechnologies N/A -297.29%-101.40% Which has stronger earnings and valuation, BLRX or ADVM? BioLineRx has higher revenue and earnings than Adverum Biotechnologies. BioLineRx is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.62-$9.22M-$8.80-0.48Adverum Biotechnologies$1M69.44-$130.93M-$7.85-0.42 Does the media prefer BLRX or ADVM? In the previous week, Adverum Biotechnologies had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Adverum Biotechnologies and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 equaled Adverum Biotechnologies'average media sentiment score. Company Overall Sentiment BioLineRx Neutral Adverum Biotechnologies Neutral Which has more risk and volatility, BLRX or ADVM? BioLineRx has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Do analysts recommend BLRX or ADVM? BioLineRx currently has a consensus price target of $26.00, indicating a potential upside of 513.21%. Adverum Biotechnologies has a consensus price target of $19.75, indicating a potential upside of 496.68%. Given BioLineRx's stronger consensus rating and higher probable upside, equities analysts plainly believe BioLineRx is more favorable than Adverum Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryBioLineRx and Adverum Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.56M$2.61B$5.83B$10.07BDividend YieldN/A48.62%5.25%4.53%P/E Ratio-0.4823.7375.5726.01Price / Sales0.62656.95536.77117.75Price / CashN/A169.9337.4259.95Price / Book1.055.2711.536.20Net Income-$9.22M$32.95M$3.29B$270.65M7 Day Performance16.80%1.34%0.44%2.77%1 Month Performance19.10%30.71%10.84%8.83%1 Year Performance-83.15%2.03%61.62%27.49% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx1.8373 of 5 stars$4.24+16.2%$26.00+513.2%-85.1%$15.56M$28.94M-0.4840High Trading VolumeADVMAdverum Biotechnologies3.4188 of 5 stars$3.08+1.7%$19.75+541.2%-50.1%$64.63M$1M-0.39190INKTMiNK Therapeutics1.9976 of 5 stars$14.24-3.9%$37.50+163.3%+92.5%$64.41MN/A-4.9430QNTMQuantum BiopharmaN/A$16.85-2.3%N/A+215.7%$64.30MN/A0.00N/ANews CoverageGap UpMNOVMediciNova1.9809 of 5 stars$1.31-2.2%$7.00+434.4%-33.0%$64.25M$1M-5.2410COEPCoeptis Therapeutics1.4418 of 5 stars$13.32+5.2%N/A+242.3%$64.23MN/A-2.302News CoveragePositive NewsShort Interest ↓IMMXImmix Biopharma3.2978 of 5 stars$2.22-3.1%$7.00+215.3%+15.7%$64.01MN/A-2.889News CoverageSLGLSol-Gel Technologies1.4584 of 5 stars$22.79+4.1%N/A+347.1%$63.49M$11.54M-18.5350Gap UpALXOALX Oncology4.0871 of 5 stars$1.17+2.6%$3.30+182.1%-48.1%$62.65MN/A-0.5340Positive NewsANLAdlai Nortye1.45 of 5 stars$1.69+0.9%$9.00+432.5%-20.4%$62.36M$5M0.00127Positive NewsGap DownKPTIKaryopharm Therapeutics3.8886 of 5 stars$7.11-7.4%$34.00+378.2%-42.6%$61.65M$145.24M-0.49380News Coverage Related Companies and Tools Related Companies ADVM Competitors INKT Competitors QNTM Competitors MNOV Competitors COEP Competitors IMMX Competitors SLGL Competitors ALXO Competitors ANL Competitors KPTI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
